A retrospective study on the efficacy and safety of Endostar with chemotherapy in EGFR-TKI-resistant NSCLC

CORC > 烟台海岸带研究所 > 中国科学院烟台海岸带研究所 > 中科院烟台海岸带研究所知识产出

	A retrospective study on the efficacy and safety of Endostar with chemotherapy in EGFR-TKI-resistant NSCLC
	Bing Han 5; Yanrong Kang 4; Haiji Wang 3; Jian Wang 5; Rong Shen 2; Shuai Liu 4; Lu Lu 4; Zhigang Sun 4; Nan Zhang 4
刊名	BMC PULMONARY MEDICINE
	2023
卷号	23 期号:1
ISSN号	1471-2466
英文摘要	Endostar is a strong angiogenesis inhibitor that is effective in treating non-small cell lung cancer (NSCLC), but the effect of Endostar in the treatment of patients with EGFR-TKI-resistant NSCLC remains unclear. We evaluated the clinical efficacy and safety of Endostar in EGFR-mutant NSCLC patients resistant to EGFR inhibition treatment.
语种	英语
内容类型	期刊论文
源URL	[http://ir.yic.ac.cn/handle/133337/33273]
专题	烟台海岸带研究所_中科院烟台海岸带研究所知识产出
作者单位	1.中国科学院烟台海岸带研究所 2.Shandong Provincial Hospital, Shandong First Medical University 3.青岛大学 4.Central Hospital, Shandong First Medical University 5.山东大学
推荐引用方式 GB/T 7714	Bing Han,Yanrong Kang,Haiji Wang,et al. A retrospective study on the efficacy and safety of Endostar with chemotherapy in EGFR-TKI-resistant NSCLC[J]. BMC PULMONARY MEDICINE,2023,23(1).
APA	Bing Han.,Yanrong Kang.,Haiji Wang.,Jian Wang.,Rong Shen.,...&Nan Zhang.(2023).A retrospective study on the efficacy and safety of Endostar with chemotherapy in EGFR-TKI-resistant NSCLC.BMC PULMONARY MEDICINE,23(1).
MLA	Bing Han,et al."A retrospective study on the efficacy and safety of Endostar with chemotherapy in EGFR-TKI-resistant NSCLC".BMC PULMONARY MEDICINE 23.1(2023).